Practicing evidence-based psychiatry- 2. Interpreting integrative literature: Systematic reviews and meta-analyses

Asian Journal of Psychiatry

Volumn 4, Issue 1, 2011, Pages 80-85

  Haj Ibrahim, Julia ^a   Tandon, Rajiv ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Antipsychotic; EBM; Evidence based; Meta analysis; Schizophrenia; Systematic review; Treatment

Indexed keywords

NEUROLEPTIC AGENT;

EVIDENCE BASED MEDICINE; EVIDENCE BASED PRACTICE; HUMAN; INTEGRATIVE MEDICINE; MEDICAL DECISION MAKING; MEDICAL LITERATURE; META ANALYSIS (TOPIC); NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SCHIZOPHRENIA; SYSTEMATIC REVIEW;

EID: 79952601625     PISSN: 18762018     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajp.2011.02.004     Document Type: Note

References (29)

1. Adams C.E., Coutinho E., Davis J.M., et al. Cochrane Schizophrenia Group: The Cochrane Library 2006, John Wiley & Sons, Chichester.
2. Buchanan R.W., Kreyenbuhl J., Kelly D.L., et al. The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements. Schizophr. Bull. 2010, 36:71-93.
3. Cook D.J., Sackett D.L., Spitzer W. Methodological guidelines for systematic reviews of randomized control trials. J. Clin. Epidemiol. 2009, 48:167-171.
4. Cook T.D., Campbell D.T. Quasi-experimentation: Design and analysis issues for field settings 2002, Rand-McNally, Chicago.
5. Davis J.M., Chen N., Glick I.D. A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry 2003, 60:553-564.
6. Systematic Reviews in Healthcare: Meta-analysis in Context 2001, BMJ Books, London. M. Egger, G.D. Smith, D.G. Altman (Eds.).
7. Geddes J., Freemantle N., Harrison P., Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000, 231:1371-1376.
8. Guyatt G.H., Rennie D. Users Guides to the Medical Literature 2001, AMA Press, Chicago.
9. Heres S., Davis J., Maino K., et al. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am. J. Psychiatry 2006, 163:185-194.
10. Higgins J.P.T., Green S. Cochrane Hand book for Systematic Reviews of Interventions 2005, John Wiley & Sons, Chichester.
11. Hugenholtz G.W., Heerdink R., Stolker J.J., et al. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J. Clin. Psychiatry 2006, 67:897-903.
12. Institute of Medicine Guidelines for Clinical Practice: From Development to Use 1992, National Academy Press.
13. Jadad A.R., Cook D.J., Jones A., et al. Methodology and reports of systematic reviews and meta-analyses. JAMA 1998, 280:278-280.
14. Jones D. Of medicine and meta-analysis. Nat. Rev. Drug Discov. 2008, 7:366-367.
15. Kane J.M., Leucht S., Carpenter D., Docherty J.P. Expert consensus guideline series. Optimizing pharmacological treatment of psychotic disorders. Introduction, methods, commentary, and summary. J. Clin. Psychiatry 2003, 64(Suppl. 12):5-19.
16. Khoshdel A., Attia J., Carney S.L. Basic concepts in meta-analysis: a primer for clinicians. Int. J. Clin. Pract. 2006, 60:1287-1294.
17. Kraemer H.C., Glick I.D., Klein D.F. Clinical trials design lessons from the CATIE study. Am. J. Psychiatry 2009, 166:1222-1228.
18. Leucht S., Corves C., Arbter D., et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 73:31-41.
19. Lieberman J.A., Stroup S.T., McEvoy J.P., et al. Effectiveness of antipsychotics in patients with chronic schizophrenia. N. Engl. J. Med. 2005, 353:1209-1223.
20. Moher D., Cook D.J., Eastwood S., et al. Improving the quality of reports of meta-analyses of randomized controlled trials: the QUOROM statement. Lancet 1999, 354:1896-1900.
21. Rankupalli B., Tandon R. Practicing evidence-based psychiatry 1. Applying a study's findings: The threats to validity approach. Asian J. Psychiatry 2010, 3:35-40.
22. Sacks H.S., Berrier J., Reitman D., et al. Meta-analyses of randomized clinical trials. N. Engl. J. Med. 1987, 316:45-455.
23. Stock W.A. Systematic coding for research synthesis. The Handbook of Research Synthesis 1994, Russell Sage, New York. H. Cooper, L.V. Hedges (Eds.).
24. Tandon R., Nasrallah H.A. Subjecting meta-analyses to closer scrutiny: little support for differential efficacy among second-generation antipsychotics. The author's reply. Arch. Gen. Psychiatry 2006, 63:935-939.
25. Tandon R., Belmaker R.H., Gattaz W.F., et al. World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia. Schizophr. Res. 2008, 100:20-38.
26. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia "Just the facts" 4. Clinical features and conceptualization. Schizophr Res. 2009, 110:1-23.
27. Tandon R., Nasrallah H.A., Keshavan M.S. Schizophrenia "Just the facts" 5. Treatment and prevention. Schizophr Res. 2010, 122:1-23.
28. Thompson S.G., Pocock S.J. Can meta-analyses be trusted?. Lancet 1991, 338:1127-1130.
29. US Department of Health and Human Services, Agency for Healthcare Policy and Research, 1992. Categories of evidence relevant to specific causal relationships and treatments. MD. AHCPR Publications, Rockville.